+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global Antiviral Drugs Market by Drug Type (Branded Drugs, Generic Drugs), Therapeutics (Acquired Immunodeficiency Syndrome Therapeutics, Hepatitis (B & C) Therapeutics, Herpes Therapeutics), End Use - Forecast 2024-2030

  • PDF Icon

    Report

  • 180 Pages
  • March 2024
  • Region: Global
  • 360iResearch™
  • ID: 4904660
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The Antiviral Drugs Market size was estimated at USD 56.22 billion in 2023, USD 59.84 billion in 2024, and is expected to grow at a CAGR of 6.54% to reach USD 87.61 billion by 2030.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Antiviral Drugs Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Antiviral Drugs Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Antiviral Drugs Market, highlighting leading vendors and their innovative profiles. These include Abacus Bioscience Inc., Abbott Laboratories, AbbVie Inc., Antiva Biosciences, Inc., AstraZeneca PLC, Aurobindo Pharma, Bristol-Myers Squibb Company, Chimerix Inc., Cipla Limited, Dr. Reddy’s Laboratories Ltd., ENYO Pharma SA, F. Hoffmann-La Roche AG, Gilead Sciences, Inc., GlaxoSmithKline PLC, Johnson & Johnson, Merck & Co., Inc., and Novartis AG.

Market Segmentation & Coverage

This research report categorizes the Antiviral Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Drug Type
    • Branded Drugs
    • Generic Drugs
  • Therapeutics
    • Acquired Immunodeficiency Syndrome Therapeutics
    • Hepatitis (B & C) Therapeutics
    • Herpes Therapeutics
    • Influenza Therapeutics
    • Pneumonia
  • End Use
    • Ambulatory Surgical Centres
    • Clinics
    • Hospitals
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects

  1. Market Penetration: It presents comprehensive information on the market provided by key players.
  2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
  3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
  4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
  5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as

  1. What is the market size and forecast of the Antiviral Drugs Market?
  2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Antiviral Drugs Market?
  3. What are the technology trends and regulatory frameworks in the Antiviral Drugs Market?
  4. What is the market share of the leading vendors in the Antiviral Drugs Market?
  5. Which modes and strategic moves are suitable for entering the Antiviral Drugs Market?

Additional Product Information:

  • The purchase of an Enterprise license allows up to ten worldwide users of an organization access to the report
  • With the purchase of this report at the Multi-user License or greater level, you will have access to one hour with an expert analyst who will help you link key findings in the report to the business issues you're addressing. This will need to be used within three months of purchase
  • Purchase of this report includes 1 year online access with quarterly updates
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website

Additional Product Information:

  • The purchase of an Enterprise license allows up to ten worldwide users of an organization access to the report
  • With the purchase of this report at the Multi-user License or greater level, you will have access to one hour with an expert analyst who will help you link key findings in the report to the business issues you're addressing. This will need to be used within three months of purchase
  • Purchase of this report includes 1 year online access with quarterly updates
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Antiviral Drugs Market, by Region
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Growing occurrence of viral diseases such as HIV, hepatitis, and influenza
5.1.1.2. Rising government and private sector expenditure in the development of antiviral drugs
5.1.1.3. Growing number of antiviral programs and campaigns to increase customer awareness
5.1.2. Restraints
5.1.2.1. High cost of antiviral drug treatment and concerns of patent expiration
5.1.3. Opportunities
5.1.3.1. Research and development in the production of vaccines for numerous viral infections and diseases
5.1.3.2. Extensive formulations to develop HIV vaccines
5.1.4. Challenges
5.1.4.1. Prevalence of alternative therapy such as homeopathy
5.2. Market Segmentation Analysis
5.3. Market Trend Analysis
5.4. Cumulative Impact of High Inflation
5.5. Porter’s Five Forces Analysis
5.5.1. Threat of New Entrants
5.5.2. Threat of Substitutes
5.5.3. Bargaining Power of Customers
5.5.4. Bargaining Power of Suppliers
5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework
6. Antiviral Drugs Market, by Drug Type
6.1. Introduction
6.2. Branded Drugs
6.3. Generic Drugs
7. Antiviral Drugs Market, by Therapeutics
7.1. Introduction
7.2. Acquired Immunodeficiency Syndrome Therapeutics
7.3. Hepatitis (B & C) Therapeutics
7.4. Herpes Therapeutics
7.5. Influenza Therapeutics
7.6. Pneumonia
8. Antiviral Drugs Market, by End Use
8.1. Introduction
8.2. Ambulatory Surgical Centres
8.3. Clinics
8.4. Hospitals
9. Americas Antiviral Drugs Market
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States
10. Asia-Pacific Antiviral Drugs Market
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam
11. Europe, Middle East & Africa Antiviral Drugs Market
11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom
12. Competitive Landscape
12.1. FPNV Positioning Matrix
12.2. Market Share Analysis, By Key Player
12.3. Competitive Scenario Analysis, By Key Player
13. Competitive Portfolio
13.1. Key Company Profiles
13.1.1. Abacus Bioscience Inc.
13.1.2. Abbott Laboratories
13.1.3. AbbVie Inc.
13.1.4. Antiva Biosciences, Inc.
13.1.5. AstraZeneca PLC
13.1.6. Aurobindo Pharma
13.1.7. Bristol-Myers Squibb Company
13.1.8. Chimerix Inc.
13.1.9. Cipla Limited
13.1.10. Dr. Reddy’s Laboratories Ltd.
13.1.11. ENYO Pharma SA
13.1.12. F. Hoffmann-La Roche AG
13.1.13. Gilead Sciences, Inc.
13.1.14. GlaxoSmithKline PLC
13.1.15. Johnson & Johnson
13.1.16. Merck & Co., Inc.
13.1.17. Novartis AG
13.2. Key Product Portfolio
14. Appendix
14.1. Discussion Guide
14.2. License & Pricing
List of Figures
FIGURE 1. ANTIVIRAL DRUGS MARKET RESEARCH PROCESS
FIGURE 2. ANTIVIRAL DRUGS MARKET SIZE, 2023 VS 2030
FIGURE 3. ANTIVIRAL DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. ANTIVIRAL DRUGS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
FIGURE 5. ANTIVIRAL DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. ANTIVIRAL DRUGS MARKET DYNAMICS
FIGURE 7. ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE, 2023 VS 2030 (%)
FIGURE 8. ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 9. ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS, 2023 VS 2030 (%)
FIGURE 10. ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 11. ANTIVIRAL DRUGS MARKET SIZE, BY END USE, 2023 VS 2030 (%)
FIGURE 12. ANTIVIRAL DRUGS MARKET SIZE, BY END USE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 13. AMERICAS ANTIVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 14. AMERICAS ANTIVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 15. UNITED STATES ANTIVIRAL DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 16. UNITED STATES ANTIVIRAL DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 17. ASIA-PACIFIC ANTIVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 18. ASIA-PACIFIC ANTIVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 21. ANTIVIRAL DRUGS MARKET, FPNV POSITIONING MATRIX, 2023
FIGURE 22. ANTIVIRAL DRUGS MARKET SHARE, BY KEY PLAYER, 2023
List of Tables
TABLE 1. ANTIVIRAL DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. ANTIVIRAL DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 6. ANTIVIRAL DRUGS MARKET SIZE, BY BRANDED DRUGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 7. ANTIVIRAL DRUGS MARKET SIZE, BY GENERIC DRUGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 9. ANTIVIRAL DRUGS MARKET SIZE, BY ACQUIRED IMMUNODEFICIENCY SYNDROME THERAPEUTICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. ANTIVIRAL DRUGS MARKET SIZE, BY HEPATITIS (B & C) THERAPEUTICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. ANTIVIRAL DRUGS MARKET SIZE, BY HERPES THERAPEUTICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. ANTIVIRAL DRUGS MARKET SIZE, BY INFLUENZA THERAPEUTICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. ANTIVIRAL DRUGS MARKET SIZE, BY PNEUMONIA, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. ANTIVIRAL DRUGS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 15. ANTIVIRAL DRUGS MARKET SIZE, BY AMBULATORY SURGICAL CENTRES, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. ANTIVIRAL DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. ANTIVIRAL DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. AMERICAS ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 19. AMERICAS ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 20. AMERICAS ANTIVIRAL DRUGS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 21. AMERICAS ANTIVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 22. ARGENTINA ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 23. ARGENTINA ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 24. ARGENTINA ANTIVIRAL DRUGS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 25. BRAZIL ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 26. BRAZIL ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 27. BRAZIL ANTIVIRAL DRUGS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 28. CANADA ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 29. CANADA ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 30. CANADA ANTIVIRAL DRUGS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 31. MEXICO ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 32. MEXICO ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 33. MEXICO ANTIVIRAL DRUGS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 34. UNITED STATES ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 35. UNITED STATES ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 36. UNITED STATES ANTIVIRAL DRUGS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 37. UNITED STATES ANTIVIRAL DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 38. ASIA-PACIFIC ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 39. ASIA-PACIFIC ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 40. ASIA-PACIFIC ANTIVIRAL DRUGS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 41. ASIA-PACIFIC ANTIVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 42. AUSTRALIA ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 43. AUSTRALIA ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 44. AUSTRALIA ANTIVIRAL DRUGS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 45. CHINA ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 46. CHINA ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 47. CHINA ANTIVIRAL DRUGS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 48. INDIA ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 49. INDIA ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 50. INDIA ANTIVIRAL DRUGS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 51. INDONESIA ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 52. INDONESIA ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 53. INDONESIA ANTIVIRAL DRUGS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 54. JAPAN ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 55. JAPAN ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 56. JAPAN ANTIVIRAL DRUGS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 57. MALAYSIA ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 58. MALAYSIA ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 59. MALAYSIA ANTIVIRAL DRUGS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 60. PHILIPPINES ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 61. PHILIPPINES ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 62. PHILIPPINES ANTIVIRAL DRUGS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 63. SINGAPORE ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 64. SINGAPORE ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 65. SINGAPORE ANTIVIRAL DRUGS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 66. SOUTH KOREA ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 67. SOUTH KOREA ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 68. SOUTH KOREA ANTIVIRAL DRUGS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 69. TAIWAN ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 70. TAIWAN ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 71. TAIWAN ANTIVIRAL DRUGS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 72. THAILAND ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 73. THAILAND ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 74. THAILAND ANTIVIRAL DRUGS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 75. VIETNAM ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 76. VIETNAM ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 77. VIETNAM ANTIVIRAL DRUGS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 78. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 79. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 80. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL DRUGS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 81. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 82. DENMARK ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 83. DENMARK ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 84. DENMARK ANTIVIRAL DRUGS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 85. EGYPT ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 86. EGYPT ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 87. EGYPT ANTIVIRAL DRUGS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 88. FINLAND ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 89. FINLAND ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 90. FINLAND ANTIVIRAL DRUGS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 91. FRANCE ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 92. FRANCE ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 93. FRANCE ANTIVIRAL DRUGS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 94. GERMANY ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 95. GERMANY ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 96. GERMANY ANTIVIRAL DRUGS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 97. ISRAEL ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 98. ISRAEL ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 99. ISRAEL ANTIVIRAL DRUGS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 100. ITALY ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 101. ITALY ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 102. ITALY ANTIVIRAL DRUGS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 103. NETHERLANDS ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 104. NETHERLANDS ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 105. NETHERLANDS ANTIVIRAL DRUGS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 106. NIGERIA ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 107. NIGERIA ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 108. NIGERIA ANTIVIRAL DRUGS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 109. NORWAY ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 110. NORWAY ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 111. NORWAY ANTIVIRAL DRUGS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 112. POLAND ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 113. POLAND ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 114. POLAND ANTIVIRAL DRUGS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 115. QATAR ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 116. QATAR ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 117. QATAR ANTIVIRAL DRUGS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 118. RUSSIA ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 119. RUSSIA ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 120. RUSSIA ANTIVIRAL DRUGS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 121. SAUDI ARABIA ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 122. SAUDI ARABIA ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 123. SAUDI ARABIA ANTIVIRAL DRUGS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 124. SOUTH AFRICA ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 125. SOUTH AFRICA ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 126. SOUTH AFRICA ANTIVIRAL DRUGS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 127. SPAIN ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 128. SPAIN ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 129. SPAIN ANTIVIRAL DRUGS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 130. SWEDEN ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 131. SWEDEN ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 132. SWEDEN ANTIVIRAL DRUGS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 133. SWITZERLAND ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 134. SWITZERLAND ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 135. SWITZERLAND ANTIVIRAL DRUGS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 136. TURKEY ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 137. TURKEY ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 138. TURKEY ANTIVIRAL DRUGS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 139. UNITED ARAB EMIRATES ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 140. UNITED ARAB EMIRATES ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 141. UNITED ARAB EMIRATES ANTIVIRAL DRUGS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 142. UNITED KINGDOM ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 143. UNITED KINGDOM ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 144. UNITED KINGDOM ANTIVIRAL DRUGS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 145. ANTIVIRAL DRUGS MARKET, FPNV POSITIONING MATRIX, 2023
TABLE 146. ANTIVIRAL DRUGS MARKET SHARE, BY KEY PLAYER, 2023
TABLE 147. ANTIVIRAL DRUGS MARKET LICENSE & PRICING

Companies Mentioned

  • Abacus Bioscience Inc.
  • Abbott Laboratories
  • AbbVie Inc.
  • Antiva Biosciences, Inc.
  • AstraZeneca PLC
  • Aurobindo Pharma
  • Bristol-Myers Squibb Company
  • Chimerix Inc.
  • Cipla Limited
  • Dr. Reddy’s Laboratories Ltd.
  • ENYO Pharma SA
  • F. Hoffmann-La Roche AG
  • Gilead Sciences, Inc.
  • GlaxoSmithKline PLC
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Novartis AG

Methodology

Loading
LOADING...

Table Information